Elutia (ELUT)
NASDAQ:ELUT
Want to see ELUT full AI Analyst Report?
Top Page
Elutia
(NASDAQ:ELUT)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.00
▲(56.25% Upside)
Action:ReiteratedDate:03/14/26
The score is held back primarily by weak financial performance (sharp revenue decline, persistent operating losses, and accelerating cash burn). Offsetting factors include a more stabilized balance sheet and liquidity following the asset sale, plus a moderately constructive earnings-call outlook on the NXT 41/41X pipeline, while technicals are mixed and valuation appears optically cheap but less reliable given cash-flow weakness.
Positive Factors
Manufacturing capacity
A single-shift manufacturing capacity of about $120M provides durable operational leverage for an initial commercial launch, reducing the need for early capital-intensive scale-ups. This supports faster time-to-market and predictable unit economics if NXT 41X attains approval and demand materializes.
Negative Factors
Accelerating cash burn
Operating cash flow deterioration (nearly doubled cash burn year-over-year) signals persistent negative cash generation that asset-sale proceeds may only partially offset. Over months, continued high burn increases reliance on external financing and dilutive capital raises, constraining strategic optionality and heightening execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Manufacturing capacity
A single-shift manufacturing capacity of about $120M provides durable operational leverage for an initial commercial launch, reducing the need for early capital-intensive scale-ups. This supports faster time-to-market and predictable unit economics if NXT 41X attains approval and demand materializes.
Read all positive factors
Elutia (ELUT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$44.65M
Dividend YieldN/A
Average Volume (3M)364.18K
Price to Earnings (P/E)0.1
Beta (1Y)0.07
Revenue Growth-22.51%
EPS Growth73.89%
CountryUS
Employees51
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.32
Shares Outstanding44,208,237
10 Day Avg. Volume362,745
30 Day Avg. Volume364,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.04
Price to Sales (P/S)2.33
P/FCF Ratio-0.61
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue1.03
Enterprise Value/Gross Profit2.10
Enterprise Value/Ebitda-1.48
Forecast
1Y Price Target
$5.00Price Target Upside681.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.63
Revenue Forecast (FY)$12.90M
Elutia Business Overview & Revenue Model
Company Description
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women...
How the Company Makes Money
Elutia generates revenue primarily through the sale of its proprietary biomaterials and regenerative medical products. The company has established a multi-faceted revenue model that includes direct sales to healthcare providers, partnerships with ...
Elutia Earnings Call Summary
Earnings Call Date:Mar 11, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call balanced clear operational and strategic progress — including an $88M asset sale, stronger margins, $44.4M (cash + escrow), regulatory submissions for NXT 41, manufacturing capacity, strong KOL engagement, and organizational hires — against ongoing near-term financial losses, modest current revenue scale, and regulatory/timing risk for the pivotal NXT 41X approval (targeted for late H1 2027). The company appears well-resourced and focused on a high-impact product opportunity, but execution risk and timeline uncertainty remain.Positive Updates
Quarterly Revenue Growth
Revenue of $3.3M in Q4 FY2025 versus $2.8M year-ago quarter, up 16% year-over-year, driven by return to direct distribution for cardiovascular and SimpliDerm product lines.
Negative Updates
Ongoing Quarterly Losses
Net loss from continuing operations of $6.5M in Q4 FY2025 (improved from $7.2M a year ago) and an adjusted EBITDA loss of $4.2M versus $3.4M in the year-ago quarter, indicating continued operating losses and an increased adjusted EBITDA shortfall.
Read all updates
Q4-2025 Updates
Positive
Negative
Quarterly Revenue Growth
Revenue of $3.3M in Q4 FY2025 versus $2.8M year-ago quarter, up 16% year-over-year, driven by return to direct distribution for cardiovascular and SimpliDerm product lines.
Read all positive updates
Company Guidance
Management guided that NXT 41 clearance is expected in 2026 with NXT 41X targeted for clearance toward the end of H1 2027 and a planned second-half‑2027 launch; the Gaithersburg facility has ~ $120M revenue capacity on one shift and the company holds $44.4M in cash (including $8M in escrow) after paying off ~ $28M of SWK debt following the $88M bioenvelope sale. Quarter highlights and runway metrics: Q4 revenue was $3.3M (+16% vs. $2.8M a year ago), adjusted gross margin 66.8% (up 12 points from 56.5%), net loss from continuing operations $6.5M (vs. $7.2M), adjusted EBITDA loss $4.2M (vs. $3.4M), and 42.8M common shares outstanding plus 4.5M pre‑funded warrants (47.3M total); the company is back in compliance with Nasdaq. Commercial and clinical context reiterated: addressing a $1.5B breast reconstruction market (~102,000 breasts/year; ADMs used in ~90% of cases), where postoperative infection is 15–20% (registry 12–37%), drains stay ~17 days and NXT 41X is designed for ~30 days of local antibiotic elution (building on EluPro’s $18M run rate and prior studies showing 62% and 82% infection reductions in comparator approaches).Elutia Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.29M | 24.38M | 24.75M | 23.85M | 47.39M |
| Gross Profit | 6.60M | 10.71M | 11.05M | 11.64M | 19.02M |
| EBITDA | -17.24M | -45.89M | -31.92M | -27.30M | -15.72M |
| Net Income | 53.38M | -53.95M | -37.66M | -32.90M | -24.83M |
Balance Sheet | |||||
| Total Assets | 62.35M | 36.13M | 43.43M | 68.84M | 67.17M |
| Cash, Cash Equivalents and Short-Term Investments | 36.35M | 13.24M | 19.28M | 16.99M | 30.39M |
| Total Debt | 7.58M | 24.74M | 23.95M | 25.45M | 23.24M |
| Total Liabilities | 34.68M | 82.39M | 82.03M | 73.87M | 53.65M |
| Stockholders Equity | 27.67M | -46.26M | -38.60M | -5.03M | 13.52M |
Cash Flow | |||||
| Free Cash Flow | -46.69M | -23.31M | -22.11M | -21.97M | -15.81M |
| Operating Cash Flow | -44.81M | -22.66M | -21.76M | -21.43M | -15.45M |
| Investing Cash Flow | 78.56M | -474.00K | 14.21M | -540.00K | -369.00K |
| Financing Cash Flow | -10.64M | 17.09M | 9.84M | 8.54M | 6.71M |
Elutia Technical Analysis
Positive
0.64
Price Trends
1.10
Positive
0.91
Positive
1.20
Negative
Market Momentum
0.02
Negative
54.94
Neutral
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELUT, the sentiment is Positive. The current price of 0.64 is below the 20-day moving average (MA) of 1.12, below the 50-day MA of 1.10, and below the 200-day MA of 1.20, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 54.94 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ELUT.
Elutia Risk Analysis
Elutia disclosed 62 risk factors in its most recent earnings report. Elutia reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Elutia Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $85.49M | -2.64 | -291.42% | ― | ― | 54.52% | |
52 Neutral | $185.82M | -0.73 | -81.69% | ― | ― | 38.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $44.65M | 0.10 | -225.83% | ― | -22.51% | 73.89% | |
50 Neutral | $31.71M | -9.21 | -76.54% | ― | -2.99% | 49.51% | |
44 Neutral | $115.39M | -4.82 | -718.54% | ― | 58.85% | 44.37% |
* Healthcare Sector Average
ELUT
Elutia
1.01
-0.87
-46.28%
IGC
IGC Pharma
0.32
0.03
10.31%
PYPD
PolyPid
4.48
1.77
65.31%
OKUR
OnKure Therapeutics
4.60
2.37
106.28%
RANI
Rani Therapeutics Holdings
0.93
-0.15
-13.70%
Elutia Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Elutia Adopts 2026 Inducement Equity Award Plan
Positive
Mar 9, 2026
On March 3, 2026, Elutia Inc.’s Board of Directors adopted the Elutia Inc. 2026 Inducement Award Plan, authorizing up to 2,000,000 shares of Class A common stock for equity awards to new hires. The plan is intended to attract, retain, and mo...
Delistings and Listing ChangesRegulatory Filings and Compliance
Elutia Regains Full Nasdaq Compliance, Strengthening Listing Status
Positive
Mar 4, 2026
Elutia has resolved prior Nasdaq compliance issues that arose in late 2025, when its Class A common stock traded below the $1.00 minimum bid price for 30 consecutive business days and its market value of listed securities fell under the $35 millio...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Elutia Faces Nasdaq Noncompliance, Considers Options to Regain Listing
Negative
Jan 2, 2026
On December 23, 2025, Elutia Inc. disclosed that it had received a notice from Nasdaq stating the company was no longer in compliance with the exchange’s $35 million minimum market value of listed securities requirement, after its market val...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.